Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dennis Slamon

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
The Clinical Respiratory Journal|January 23, 2018
Significance of tumor-associated autoantibodies in the early diagnosis of lung cancerQiang Du, Ruofei Yu, Han Wang, et al.
Gynecologic Oncology|December 26, 2013
POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancerBeth Y Karlan, Judy Dering, Christine Walsh, et al.
Cancer Gene Therapy|June 26, 2002
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerRichard E Buller, Ingo B Runnebaum, Beth Y Karlan, et al.
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
The Lancet. Oncology|February 3, 2019
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysisEverardo D Saad, Pierre Squifflet, Tomasz Burzykowski, et al.
Scientific Reports|February 16, 2017
An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cellsJianing Jiang, Hui Zhao, Weiliang Shu, et al.
The American Journal of Pathology|April 8, 2009
Frequent activating mutations of PIK3CA in ovarian clear cell carcinomaKuan-Ting Kuo, Tsui-Lien Mao, Siân Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerNicholas Robert, Brian Leyland-Jones, Lina Asmar, et al.
Science (New York, N.Y.)|September 10, 2010
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinomaSiân Jones, Tian-Li Wang, Ie-Ming Shih, et al.
Plos One|March 4, 2014
PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencingBin Liu, Samuel Tahk, Kathleen M Yee, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
The Clinical Respiratory Journal|January 23, 2018
Significance of tumor-associated autoantibodies in the early diagnosis of lung cancerQiang Du, Ruofei Yu, Han Wang, et al.
Gynecologic Oncology|December 26, 2013
POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancerBeth Y Karlan, Judy Dering, Christine Walsh, et al.
Cancer Gene Therapy|June 26, 2002
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancerRichard E Buller, Ingo B Runnebaum, Beth Y Karlan, et al.
Cancer Gene Therapy|June 26, 2002
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500Richard E Buller, Mark S Shahin, Jo Ann Horowitz, et al.
The Lancet. Oncology|February 3, 2019
Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysisEverardo D Saad, Pierre Squifflet, Tomasz Burzykowski, et al.
Scientific Reports|February 16, 2017
An integrated microfluidic device for rapid and high-sensitivity analysis of circulating tumor cellsJianing Jiang, Hui Zhao, Weiliang Shu, et al.
The American Journal of Pathology|April 8, 2009
Frequent activating mutations of PIK3CA in ovarian clear cell carcinomaKuan-Ting Kuo, Tsui-Lien Mao, Siân Jones, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2006
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancerNicholas Robert, Brian Leyland-Jones, Lina Asmar, et al.
Science (New York, N.Y.)|September 10, 2010
Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinomaSiân Jones, Tian-Li Wang, Ie-Ming Shih, et al.
Plos One|March 4, 2014
PIAS1 regulates breast tumorigenesis through selective epigenetic gene silencingBin Liu, Samuel Tahk, Kathleen M Yee, et al.
Pageof 5